ADMA Biologics(US:ADMA) ZACKS·2025-06-20 22:51Core Viewpoint - Adma Biologics is experiencing a decline in stock performance, with a notable drop in the past month, while upcoming earnings are expected to show positive growth in EPS and revenue [1][2][3]. Company Performance - The stock price of Adma Biologics closed at $17.74, reflecting a decrease of 2.15% from the previous day, underperforming compared to the S&P 500's loss of 0.22 [1] - Over the past month, the stock has decreased by 10.07%, contrasting with the Medical sector's stability and the S&P 500's slight gain of 0.45% [1] Earnings Expectations - Analysts anticipate an EPS of $0.14 for the upcoming earnings report, representing a 7.69% increase year-over-year [2] - Revenue is expected to reach $121.1 million, indicating a 12.98% growth compared to the same quarter last year [2] Full Year Projections - For the full year, earnings are projected at $0.67 per share, reflecting a 36.73% increase from the previous year [3] - Revenue for the year is estimated at $505.8 million, which would be an 18.61% rise from the prior year [3] Analyst Estimates - Recent adjustments to analyst estimates for Adma Biologics are crucial, as they often indicate short-term business trends and analysts' confidence in the company's profitability [4] - Upward revisions in estimates suggest positive sentiment regarding the company's operational performance [4] Zacks Rank and Valuation - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate remaining unchanged over the last 30 days [6] - The company is trading at a Forward P/E ratio of 27.26, which is higher than the industry average of 19.86 [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries [7] - The Zacks Industry Rank indicates that the top-rated industries tend to outperform the lower-rated ones by a factor of 2 to 1 [8]